**Terbinafine** (Lamisil)

**Indication(s):** Fungal Skin Infection (Topical)

**Contraindications:** Hypersensitivity to terbinafine.

**Precautions:** Avoid in pregnancy

**Drug Interactions:** No known drug interactions for the cream formulation.

**Adverse effects:** (1-10%) Flaking or peeling of the skin (skin exfoliation), itching (pruritus). (<1%) Skin lesions, scabbing, change in the color of the skin (pigmentation disorder), redness of the skin (erythema), skin burning sensation, pain, application site pain, application site irritation.

**Pharmacology:** Inhibits ergosterol synthesis which detrimentally alters fungal cell. Increased membrane permeability and accumulation of metabolic products result in growth inhibition and cell death.

**Dosage and Administration:** As per *Topical Fungal Infections Protocol*: apply topically to affected areas BID for >1 but <4 weeks.